Improved Survival Time Trends for Glioblastoma Using the SEER 17 Population-based Registries

Overview

Journal J Neurooncol

Publisher Springer

Date 2011 Oct 11

PMID 21984115

Citations 265

Authors

Matthew Koshy

John L Villano

Therese A Dolecek

Andrew Howard

Usama Mahmood

Steven J Chmura

Ralph R Weichselbaum

Bridget J McCarthy

Affiliations

Soon will be listed here.

Abstract

The EORTC/NCIC 22981/26981 study demonstrated an improvement in median overall survival (OS) from 12.1 to 14.6 months in patients with glioblastoma (GBM) who received temozolomide with post-operative radiotherapy (RT). The current study was performed to determine if those results translated into a survival benefit in a population-based cohort. Patients diagnosed between 2000 and 2006 with a GBM who underwent surgery and post-operative RT were selected from the Surveillance, Epidemiology and End Results database. Patients were grouped into time periods: 2000-2001, 2002-2003, 2004 and 2005-2006 (which represented those treated after the EORTC/NCIC trial presentation in 2004). Relative survival (RS) was estimated by the Kaplan-Meier method, and Cox multivariable regression modeling was used to estimate proportional hazard ratios (HR). Over time, there was improvement in the median and 2-year RS of 12 months and 15% for 2000-2001, 13 months and 19% for 2002-2003, 14 months and 24% for 2004, and 15 months and 26% for 2005-2006 (P < 0.0001 compared to 2000-2001 and 2002-2003; P = 0.07 compared to 2004). The estimated adjusted HR showed that patients diagnosed in 2005-2006 had significantly improved survival when compared to patients diagnosed in 2000-2001 (HR = 0.648, 95% CI 0.604-0.696). The median and 2 year RS of 15 months and 26% in 2005-2006 was similar to the median and 2 year OS of 14.6 months and 26% seen in the EORTC/NCIC phase III study. These results are encouraging and suggest that the current treatment of glioblastoma nationwide is now associated with an improved survival compared to previous time cohorts.

Citing Articles

Distant origin of glioblastoma recurrence: neural stem cells in the subventricular zone serve as a source of tumor reconstruction after primary resection.

Li X, Kim H, Yoo J, Lee Y, Nam C, Park J Mol Cancer. 2025; 24(1):64.

PMID: 40033380 PMC: 11877783. DOI: 10.1186/s12943-025-02273-2.

Reduced Treatment Volumes for Glioblastoma Associated With Lower Rates of Radionecrosis and Lymphopenia: A Pooled Analysis.

Matsui J, Swanson D, Allen P, Perlow H, Bradshaw J, Beckham T Adv Radiat Oncol. 2025; 10(3):101717.

PMID: 40028224 PMC: 11871440. DOI: 10.1016/j.adro.2025.101717.

Artificial Intelligence-Assisted Drug and Biomarker Discovery for Glioblastoma: A Scoping Review of the Literature.

Conte L, Caruso G, Philip A, Cucci F, De Nunzio G, Cascio D Cancers (Basel). 2025; 17(4).

PMID: 40002166 PMC: 11852502. DOI: 10.3390/cancers17040571.

Prognostic Modeling of Overall Survival in Glioblastoma Using Radiomic Features Derived from Intraoperative Ultrasound: A Multi-Institutional Study.

Cepeda S, Esteban-Sinovas O, Singh V, Moiyadi A, Zemmoura I, Del Bene M Cancers (Basel). 2025; 17(2).

PMID: 39858063 PMC: 11763491. DOI: 10.3390/cancers17020280.

Tingling, Numbness, and Underlying Malignancy: A Case Report of Glioblastoma Multiforme.

Bhatia R, Singh H, Sadeque J, Mathur K Cureus. 2025; 16(12):e76081.

PMID: 39835015 PMC: 11743905. DOI: 10.7759/cureus.76081.

References

Curran Jr W, Scott C, Horton J, Nelson J, Weinstein A, Fischbach A . Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst. 1993; 85(9):704-10. DOI: 10.1093/jnci/85.9.704. View

Yu J, Gross C, Wilson L, Smith B . NCI SEER public-use data: applications and limitations in oncology research. Oncology (Williston Park). 2009; 23(3):288-95. View

Gorlia T, van den Bent M, Hegi M, Mirimanoff R, Weller M, Cairncross J . Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. Lancet Oncol. 2007; 9(1):29-38. DOI: 10.1016/S1470-2045(07)70384-4. View

Lutterbach J, Sauerbrei W, Guttenberger R . Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlenther Onkol. 2003; 179(1):8-15. DOI: 10.1007/s00066-003-1004-5. View

Simon J, Cornu P, Boisserie G, Hasboun D, Tep B, Hardiman C . Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys. 2002; 53(1):67-74. DOI: 10.1016/s0360-3016(01)02804-8. View

Larson D, Suplica J, Chang S, Lamborn K, McDermott M, Sneed P . Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neuro Oncol. 2004; 6(2):119-26. PMC: 1871978. DOI: 10.1215/s1152851703000425. View

Prisco F, Weltman E, de Hanriot R, Brandt R . Radiosurgical boost for primary high-grade gliomas. J Neurooncol. 2002; 57(2):151-60. DOI: 10.1023/a:1015757322379. View

Buckner J . Factors influencing survival in high-grade gliomas. Semin Oncol. 2004; 30(6 Suppl 19):10-4. DOI: 10.1053/j.seminoncol.2003.11.031. View

Jeremic B, Milicic B, Grujicic D, Dagovic A, Aleksandrovic J . Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J Cancer Res Clin Oncol. 2003; 129(8):477-84. DOI: 10.1007/s00432-003-0471-5. View

10.

Narayana A, Yamada J, Berry S, Shah P, Hunt M, Gutin P . Intensity-modulated radiotherapy in high-grade gliomas: clinical and dosimetric results. Int J Radiat Oncol Biol Phys. 2006; 64(3):892-7. DOI: 10.1016/j.ijrobp.2005.05.067. View

11.

Stupp R, van den Bent M, Hegi M . Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005; 5(3):198-206. DOI: 10.1007/s11910-005-0047-7. View

12.

Linz U . Commentary on Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial (Lancet Oncol. 2009;10:459-466). Cancer. 2010; 116(8):1844-6. DOI: 10.1002/cncr.24950. View

13.

Lamborn K, Chang S, Prados M . Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol. 2004; 6(3):227-35. PMC: 1871999. DOI: 10.1215/S1152851703000620. View

14.

DeAngelis L . Brain tumors. N Engl J Med. 2001; 344(2):114-23. DOI: 10.1056/NEJM200101113440207. View

15.

Cardinale R, Won M, Choucair A, Gillin M, Chakravarti A, Schultz C . A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boost for supratentorial glioblastoma multiforme: RTOG 0023. Int J Radiat Oncol Biol Phys. 2006; 65(5):1422-8. DOI: 10.1016/j.ijrobp.2006.02.042. View

16.

Stupp R, Hegi M, Mason W, van den Bent M, Taphoorn M, Janzer R . Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10(5):459-66. DOI: 10.1016/S1470-2045(09)70025-7. View

17.

Lacroix M, Abi-Said D, Fourney D, Gokaslan Z, Shi W, Demonte F . A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2002; 95(2):190-8. DOI: 10.3171/jns.2001.95.2.0190. View

18.

Laperriere N, Zuraw L, Cairncross G . Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol. 2002; 64(3):259-73. DOI: 10.1016/s0167-8140(02)00078-6. View

19.

Westphal M, Hilt D, Bortey E, Delavault P, Olivares R, Warnke P . A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol. 2003; 5(2):79-88. PMC: 1920672. DOI: 10.1093/neuonc/5.2.79. View

20.

Scott C, Scarantino C, Urtasun R, Movsas B, Jones C, Simpson J . Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. Int J Radiat Oncol Biol Phys. 1998; 40(1):51-5. DOI: 10.1016/s0360-3016(97)00485-9. View